<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Tvrd — News on 6ix</title>
    <link>https://6ix.com/company/tvrd</link>
    <description>Latest news and press releases for Tvrd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/tvrd" rel="self" type="application/rss+xml" />
    <item>
      <title>Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-to-participate-in-the-raymond-james-biotech-innovation-symposium-97</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-to-participate-in-the-raymond-james-biotech-innovation-symposium-97</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-fourth-quarter-and-full-year-2025-results-and-provides-business-update-4</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-fourth-quarter-and-full-year-2025-results-and-provides-business-update-4</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-upcoming-investor-130000708</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-upcoming-investor-130000708</guid>
      <pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
      <description>HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences: JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Link here Oppenheimer 36th Annual Healt</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-present-44th-annual-210500525</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-present-44th-annual-210500525</guid>
      <pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
      <description>Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held Jan</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-further-phase-130000519</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-further-phase-130000519</guid>
      <pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
      <description>Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 t</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-piper-sandler-130000391</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-piper-sandler-130000391</guid>
      <pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
      <description>HOUSTON, November 18, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company’s management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-third-quarter-210100038</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-third-quarter-210100038</guid>
      <pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
      <description>HOUSTON, November 13, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-jefferies-global-130000104</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-jefferies-global-130000104</guid>
      <pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
      <description>HOUSTON, November 04, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-provides-preliminary-data-113000634</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-provides-preliminary-data-113000634</guid>
      <pubDate>Mon, 13 Oct 2025 11:30:00 GMT</pubDate>
      <description>HOUSTON, October 13, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF).</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-cantor-global-120000800</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-cantor-global-120000800</guid>
      <pubDate>Thu, 21 Aug 2025 12:00:00 GMT</pubDate>
      <description>HOUSTON, August 21, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-second-quarter-200100489</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-second-quarter-200100489</guid>
      <pubDate>Thu, 14 Aug 2025 20:01:00 GMT</pubDate>
      <description>HOUSTON, August 14, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-btig-virtual-120000962</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-participate-btig-virtual-120000962</guid>
      <pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
      <description>HOUSTON, July 15, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-completion-enrollment-120000189</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-completion-enrollment-120000189</guid>
      <pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
      <description>HOUSTON, May 27, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical t</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-first-quarter-200500751</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-first-quarter-200500751</guid>
      <pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
      <description>HOUSTON, May 13, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference</title>
      <link>https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-presentation-american-110000364</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/tvardi-therapeutics-announces-presentation-american-110000364</guid>
      <pubDate>Tue, 06 May 2025 11:00:00 GMT</pubDate>
      <description>HOUSTON, May 06, 2025--Tvardi Therapeutics, Inc. (&quot;Tvardi&quot;) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco.</description>
    </item>
    <item>
      <title>Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics</title>
      <link>https://6ix.com/company/tvrd/news/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics</guid>
      <pubDate>Mon, 14 Apr 2025 04:00:00 GMT</pubDate>
      <description>STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the</description>
    </item>
    <item>
      <title>Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split</title>
      <link>https://6ix.com/company/tvrd/news/cara-therapeutics-announces-effective-date-of-1-for-12-reverse-stock-split</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/cara-therapeutics-announces-effective-date-of-1-for-12-reverse-stock-split</guid>
      <pubDate>Fri, 27 Dec 2024 05:00:00 GMT</pubDate>
      <description>STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split</description>
    </item>
    <item>
      <title>Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement</title>
      <link>https://6ix.com/company/tvrd/news/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement</guid>
      <pubDate>Wed, 18 Dec 2024 05:00:00 GMT</pubDate>
      <description>Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven</description>
    </item>
    <item>
      <title>Cara Therapeutics Announces Exploration of Strategic Alternatives</title>
      <link>https://6ix.com/company/tvrd/news/cara-therapeutics-announces-exploration-of-strategic-alternatives</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/cara-therapeutics-announces-exploration-of-strategic-alternatives</guid>
      <pubDate>Thu, 11 Jul 2024 04:00:00 GMT</pubDate>
      <description>Piper Sandler &amp; Co. to act as financial advisor STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that</description>
    </item>
    <item>
      <title>Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica</title>
      <link>https://6ix.com/company/tvrd/news/cara-therapeutics-announces-outcome-of-part-a-of-kourage-1-study-evaluating-oral-difelikefalin-in-notalgia-paresthetica</link>
      <guid isPermaLink="true">https://6ix.com/company/tvrd/news/cara-therapeutics-announces-outcome-of-part-a-of-kourage-1-study-evaluating-oral-difelikefalin-in-notalgia-paresthetica</guid>
      <pubDate>Wed, 12 Jun 2024 04:00:00 GMT</pubDate>
      <description>– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore</description>
    </item>
  </channel>
</rss>